No Prescription |
 |
 | ||
|
Capoten Oral Soln Generic Captopril |
|
| ||
No Prescription » Prescription Drugs 3 » Capoten Oral Soln Generic Captopril Hypertension:Capoten is indicated for the treatment of hypertension in adult and paediatric patients. It may be used alone or in combination with other antihypertensive agents especially thiazide-type diuretics. The blood pressure lowering effects of Capoten and thiazides are additive.Heart Failure:Capoten is indicated for the treatment of patients with heart failure. In such patients it is recommended that Capoten be administered with a diuretic.Myocardial Infarction:Capoten is indicated in clinically stable patients with asymptomatic and symptomatic left ventricular dysfunction following myocardial infarction to improve survival and reduce the risk of recurrent myocardial infarction or hospitalisation for heart failure.Diabetic Nephropathy:Capoten is indicated for the treatment of diabetic nephropathy in Type 1 diabetes with or without hypertension. In these patients Capoten prevents the progression of renal disease and reduces associated clinical sequelae (dialysis renal transplantation and death). Buy Capoten Oral Soln Generic Captopril and other Prescription Drugs 3 products online at Medstore. 5458
About Capoten Oral Soln Generic Captopril: Product Type: Prescription Drugs 3 Capoten Oral Soln ( Generic Captopril ) Capoten Oral Soln (Generic Captopril) Generic Captopril 5mg/mL 95mL Generic Captopril Capoten Oral Soln
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
